公开(公告)号：US20240059772A1

公开(公告)日：2024-02-22

申请号：US18339837

申请日：2023-06-22

申请人： BioNTech AG ,  Astellas Pharma Inc. ,  TRON - Translationle Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz

发明人： Ugur Sahin ,  Ozlem Tureci ,  Korden Walter ,  Meike Wagner ,  Maria Kreuzberg ,  Sabine Hacker ,  Stefan Jacobs

IPC分类号： C07K16/28 ,  G01N33/574 ,  A61K47/68 ,  A61K33/243 ,  A61K31/337 ,  A61K31/5365 ,  A61K31/7048 ,  A61K31/7064 ,  A61K39/395 ,  A61N5/10 ,  C07K16/30

CPC分类号： C07K16/28 ,  G01N33/57484 ,  A61K47/6851 ,  A61K33/243 ,  A61K31/337 ,  A61K31/5365 ,  A61K31/7048 ,  A61K31/7064 ,  A61K39/39558 ,  A61N5/10 ,  C07K16/30 ,  G01N33/57492 ,  G01N2800/52 ,  C07K2317/73 ,  A61K2039/505

摘要： The present invention provides methods for diagnosis or treatment of cancer diseases involving cancer stem cells comprising targeting CLDN6. In particular, the present invention provides a method of determining cancer stem cells comprising detecting cells expressing CLDN6. Furthermore, the present invention provides a method of treating or preventing cancer comprising inhibiting and/or eliminating cancer stem cells by administering an antibody having the ability of binding to CLDN6 to a cancer patient.